ABSTRACT: NR2E3, a photoreceptor-specific nuclear receptor (PNR), represses cone-specific genes and activates several rod-specific genes. In humans, mutations in NR2E3 have been associated with the recessively-inherited enhanced short-wavelength sensitive Scone syndrome (ESCS) and, recently, with autosomal dominant (ad) retinitis pigmentosa (RP) (adRP). In the present work, we describe two additional families affected by adRP that carry a heterozygous c.166G4A (p.G56R) mutation in the NR2E3 gene. Functional analysis determined the dominant negative activity of the p.G56R mutant protein as the molecular mechanism of adRP. Interestingly, in one pedigree, the most common causal variant for ESCS (p.R311Q) cosegregated with the adRP-linked p.G56R mutation, and the compound heterozygotes exhibited an ESCS-like phenotype, which in 1 of the 2 cases was strikingly ''milder'' than the patients carrying the p.G56R mutation alone. Impaired repression of cone-specific genes by the corepressors atrophin-1 (dentatorubral-pallidoluysian atrophy [DRPLA] gene product) and atrophin-2 (arginineglutamic acid dipeptide repeat [RERE] protein) appeared to be a molecular mechanism mediating the beneficial Introduction NR2E3 (MIM] 604485), also called photoreceptor-specific nuclear receptor (PNR), is a photoreceptor-specific transcription factor of the nuclear hormone receptor superfamily [Kobayashi et al., 1999] . NR2E3 exhibits the evolutionary-conserved modular structure of nuclear receptors, namely a highly-conserved DNAbinding domain (DBD) that specifically binds to consensus binding sites located in promoters of target genes, and a ligandbinding domain (LBD) Kobayashi et al., 1999] . Although NR2E3 acts as a transcriptional activator of several rodspecific genes, in synergy with the cone-rod homeobox (CRX; MIM] 602225) and the neural retina leucine zipper (NRL; MIM] 162080) transcription factors [Cheng et al., 2004 [Cheng et al., , 2006 , a physiological function of NR2E3 is thought to be repression of cone-specific genes in rods . For instance, transgenic mice ectopically expressing NR2E3 under the control of the CRX promoter in photoreceptor precursor cells showed a suppression of cone-specific gene expression; consequently, differentiation of cone photoreceptor cells was suppressed, but nonfunctional rod-like photoreceptor cells were generated [Cheng et al., 2006] . The critical role of NR2E3 for the regulation of photoreceptor generation became evident in the rd7/rd7 mice, a spontaneous loss-of-function model of NR2E3 [Akhmedov et al., 2000; Haider et al., 2001] . In rd7/rd7 retinas, blue (S-cone) opsin expressing cone cells are generated throughout postnatal life. This abnormal number of cones leads to laminar disorganization and fragmentation of the retina [Akhmedov et al., 2000; Haider et al., 2001 Haider et al., , 2006 . NR2E3 might therefore be needed to suppress the cone generation program in late mitotic retinal progenitor cells [Haider et al., 2006] .
In humans, mutations in NR2E3 have been associated with the recessively-inherited enhanced short-wavelength sensitive S-cone syndrome (ESCS; MIM] 268100) [Haider et al., 2000] . ESCS is characterized by unique full-field and spectral electroretinographic findings with hyperfunction of S-cones (''blue'' cones) and impaired M-cone, L-cone, and rod functions [Gouras, 1981; Gouras et al., 1985; Jacobson et al., 1990; Marmor et al., 1990] . To date, 20 different mutations located in the evolutionary-conserved DBD and LBD of NR2E3 have been linked to ESCS, with c.932G4A (p.R311Q) being the most prevalent [Haider et al., 2000; Hayashi et al., 2005; Milam et al., 2002; Sharon et al., 2003; Wright et al., 2004] .
Recently, a c.166G4A (p.G56R) mutation in the NR2E3 gene was reported as being one of the more common single causal mutations for autosomal-dominant (ad) retinitis pigmentosa (RP) (adRP), termed RP37 (MIM] 611131) [Coppieters et al., 2007; Gire et al., 2007] . The phenotype corresponded to that seen in classic adRP, with progressive degeneration of rods and subsequent involvement of cones.
In the present work, we functionally characterized the p.G56R mutation that we had previously identified [Bouayed-Tiab et al., 2006] , and showed that dominant negative activity of the mutant protein was the molecular mechanism underlying adRP. We also analyzed a pedigree in which adRP and ESCS segregate due to the presence of a p.G56R/wild-type or a p.G56R/p.R311Q genotype. We addressed the mechanisms by which the recessive trans-acting p.R311Q (ESCS) mutation has a protective effect when uncovered by the dominant cis-acting p.G56R (adRP) mutation. Additionally, we identified atrophin-1, the dentatorubral-pallidoluysian atrophy (DRPLA) gene product [Yazawa et al., 1995] , and the related atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein [Yanagisawa et al., 2000] as corepressors of NR2E3 and showed that impaired corepressor activity may be the molecular basis of ESCS.
Materials and Methods

Patient Information and Examination
Studies were conducted under protocols approved by the Institutional Review Boards of Hô pital Ophtalmique Jules-Gonin for the Swiss family and of Columbia University for the American family of Jewish origin. Written informed consent for clinical examination and DNA analysis was obtained from all individuals. Each patient and several unaffected family members were examined by standard ophthalmological methods, including fundus photography and electroretinography (ERG); the older subjects were examined over a 25-year period.
To determine dark-adapted thresholds, a Goldmann-Weekers adaptometer (Haag-Streit, Bern, Switzerland) was used. Since only the final dark-adapted threshold, and not dark adaptation curves, was being determined, a preadapting light was unnecessary. Final dark-adapted thresholds were obtained in units of luminance (footlamberts) and were compared to values of normal controls on the same adaptometer. Color vision was normal in all subjects on the Farnsworth Panel D-15.
For ERG measurements, the light source was a Grass stimulator recessed in a ganzfeld dome. The subjects were first studied in the dark-adapted state using spectral stimuli obtained by the use of four Kodak Wratten filters (29 [red] Then the subjects were light-adapted with a steady ganzfeld background of 53 footlamberts and the responses to the four spectral stimuli were obtained again (Supplementary Fig. S1A ; available online at http://www.interscience.wiley.com/jpages/1059-7794/suppmat). A complete description of this methodology has been published [Gouras et al., 1985] . In addition, ERG responses were obtained to white light stimulation. Responses were detected at the cornea by Burian-Allen bipolar contact lens electrodes and amplified by a Nicolet computer system with low noise amplifiers, averaging usually 50 to 100 responses to the same flash presented every second (Alden Products Company, Brockton, MA). In one case (proband Patient II-1) a spectral sensitivity function for the ERG was obtained in the dark-and light-adapted state by defining the relationship between ERG amplitude and the energy of stimulation using four additional Wratten filters and then determining the energy required for each filter to produce a constant slightly suprathreshold response in the dark-and lightadapted state ( Supplementary Fig. S1B ).
Reagents
If not stated otherwise, chemical reagents were from FlukaSigma (Buchs, Switzerland); oligonucleotides from Eurogentec (Liège, Belgium) and Microsynth (Balgach, Switzerland); DNA purification kits from Macherey-Nagel (Düren, Germany); plasticware from Techno Plastic Products (Trasadingen, Switzerland); and cell culture reagents from Invitrogen (Paisley, UK).
Genotyping, Linkage Analysis, and Mutation Detection
Blood samples were obtained for DNA analysis from 11 out of 13 affected and 16 out of 18 nonaffected members of the Swiss family and all members of the American family. DNA was isolated from leukocytes (Nucleon Bacc2; Amersham Biosciences, Otelfingen, Switzerland). As inheritance was clearly dominant in the Swiss family, linkage analysis was performed in a two-step approach. First, two markers flanking each of the 15 most frequent adRP loci (CA4, CRX, FSCN2, GUCA1B, IMPDH1, NRL, PRPF3, PRPF8, PRPF31, RDS, RHO, ROM1, RP1, RP9, and SEMA4) were chosen and haplotypes were established. Second, because all loci were excluded, a genome-wide linkage analysis was performed with 380 microsatellites from the ABI linkage mapping set 2.5 (average distance between markers: 10 cM). Haplotypes were determined with Autoscan V1.01B and logarithm of odds (lod) scores were calculated using Mlink V5.1 under the assumption of autosomal dominant inheritance with complete penetrance, a neomutation rate of 0.001, and equal allele frequency (http://www.genetics.ucla.edu/software/autoscan). Heteroduplex analysis of NR2E3 amplicons was performed using an automated denaturing high-performance liquid chromatography (DHPLC) instrument (WAVE; Transgenomic, Glasgow, UK). Amplicons with abnormal retention time were directly sequenced on an ABI 3100XL DNA sequencer (Applied Biosystems [ABI] , Foster City, CA) using a Big Dye Terminator Labeling Kit (ABI). Finally, after identification of the p.G56R mutation, the potential promoter region, exonic, and intronic sequences of the NR2E3 gene were directly sequenced for all patients after PCR amplification.
NR2E3 cDNA Mutagenesis
The cDNA bases were numbered according to the human NR2E3 reference sequence in GenBank NM_014249.2, where 11 corresponds to the A of the ATG translation initiation codon. Mutagenesis was performed according to the QuikChange s II Site-Directed Mutagenesis Kit using PfuUltra polymerase (Stratagene, Cedar Creek, TX). Briefly, pcDNA3.1/HisC-hNR2E3 was amplified with forward 5 0 -GTGCGGAGACAGC AGCAGCAGGAAGCACTATGGC-3 0 and reverse 5 0 -GCCATAGTG CTTCCTGCTGCTGCTGTCTCCGCAC-3 0 oligonucleotides to obtain the pcDNA3.1/HisC-hNR2E3-G56R plasmid. To obtain the pcDNA3.1/HisC-hNR2E3R311Q plasmid, oligonucleotides 5 0 -CC TGCAGGAAACTATCTCTCGGTTCCAGGCATTGGCGG-3 0 and 5 0 -CCGCCAATGCCTGGAACCGAGAGATAGTTTCCTGCAGG-3 0 were used.
Transactivation Assays
A mouse S-opsin promoter fragment (opn1sw) spanning nucleotides À736/117 relative to the ATG was amplified with oligonucleotides 5 0 -GGGGTACCGGTGTGATGATGCTGACAAG-3 0 and 5 0 -CGGGATCCTCATCCTCTC CTGACATCTC-3 0 , verified by sequencing, and then subcloned into KpnI/BglII sites of the pGL2-promoter luciferase reporter vector (Promega, Madison, WI). Human embryonic kidney (HEK) 293T cells were grown in DMEM containing 10% FCS and penicillin/streptomycin (Invitrogen). Cells were plated in 12-well plates and transfected at a confluence of 30% with the calcium phosphate method (ProFection s ; Promega). Per well, 30 ng of each of the expression vectors pcDNA3.1/HisC-hNR2E3 (wild-type, p.R311Q, and p.G56R), pcDNA3.1/HisC-hCRX, and pMT-NRL were used , together with 500 ng of the luciferase reporter constructs for rhodopsin promoter BR225-Luc , for M-opsin promoter Mop250-Luc , or for the S-opsin promoter (see above). As internal standard, 50 ng of plasmid CMVb (Clontech, Mountain View, CA) encoding b-galactosidase was used. For corepressor studies, 33, 66, or 100 ng of the pCMX expression vectors encoding FLAG-tagged atrophin-1, atrophin-2, and nuclear receptor corepressor (NCoR) were transfected [Hörlein et al., 1995; Wang et al., 2006] . To keep the total transfected DNA quantity constant, appropriate quantities of pcDNA3.1/HisC and pCMX-FLAG empty vectors were added in all experiments. Enzymatic activities were assessed with the Luciferase Assay System (Promega) and standard b-Gal assay. For corepressor studies, we considered only experiments where the b-galactosidase activities were comparable between all wells.
Electrophoretic Mobility Shift Assay (EMSA)
The pcDNA3.1/HisC-hNR2E3 expression vectors were used for in vitro transcription/translation (TNT; Promega). In vitro DNAbinding was tested on the annealed oligonucleotides NR2E3REfor (5 0 -CCTTTAAAAGTCAAAAGTCAACTTCCAA-3 0 ) and NR2E3R-Erev (5 0 -TTCCGTTGGAAGTTGACTTTTGACTTTT-3 0 ). Radiolabeling by Klenow fill-in with 30 mCi of [a-
32 P]dATP (3,000 Ci/ mmol) (Hartmann Analytik, Braunschweig, Germany) and subsequent probe purification on Sephadex G-50 columns (Roche, Basel, Switzerland) was according to the manufacturer's instructions. DNA-binding reactions were carried out in 20 ml of 10 mM Tris (pH 7.5), 160 mM KCl, 1 mM DTT, 10% glycerol, 10 mg of sonicated salmon sperm DNA (Roche), and 2 mg of poly(dI-dC) with indicated amounts of programmed reticulocyte lysate. For competition experiments, unlabeled probes were added in 2-to 100-fold molar excess. After a 15-min incubation on ice, 1 ng of 32 P-labeled probe was added, and incubations were continued for an additional 15 min at room temperature. For ''supershift'' experiments, 2 mg of rabbit polyclonal anti-human NR2E3 (1 mg/ml; Millipore, Billerica, MA) was added to the reaction and incubation proceeded for another 10 min. DNAprotein complexes were separated from free probe on native 4% polyacrylamide gel in 0.5 Â Tris/borate/EDTA (TBE) buffer, gels were dried and revealed by phosphorimaging (GE Healthcare, Piscataway, NJ).
Animal Handling
All experiments performed in this study were in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Veterinary Service of the State of Valais (Switzerland). C57BL/6 mice (RCC, Basel, Switzerland) were kept in a 12-hr light-dark cycle with unlimited access to food and water.
Chromatin-Immunoprecipitations
Experiments were carried out on six retinas exactly as described , except protein-protein cross-linking of cells in 1.5 mM ethylene glycolbis[succinimidyl succinate] (EGS) preceded formaldehyde fixation [Zeng et al., 2006] . For immunoprecipitation, a sheep polyclonal anti-atrophin-1 (A-19) antibody was used (Santa Cruz Biotechnology, Santa Cruz, CA).
In Situ Hybridization
Eyes were enucleated, rinsed in 1 Â PBS-DEPC, fixed for 2 hr with 4% paraformaldehydeÀ1 Â PBS-DEPC and included for overnight in 30% sucrose-1 Â PBS-DEPC. Eyes were sectioned at À211C on a Leica CM1900 cryostat (Leica Microsystems, Heerbrugg, Switzerland) and 12-mm sections recovered on SuperFrost s Plus microscope slides (Menzel Gläser, Braunschweig, Germany) pretreated with Vectabond (Vector Laboratories, Burlingame, CA). A 250 bp-probe for atrophin-1 was amplified from reverse-transcribed mouse brain mRNA with primers 5 0 -CTTCGTCACCAGCTTTTTGC-3 0 and 5 0 -GCTTGTCACTCTCC TTCTTC-3 0 , and then subcloned into the pGEM s -T Easy vector (Promega). DIG-labeled sense and antisense probes were tested by immunodot blotting. In situ hybridizations were carried out at 481C as previously described [Braissant and Wahli, 1998 ].
Results
Mutations in NR2E3 Cause Dominant or Recessive Retinal Diseases
During our systematic screening of families with various forms of RP in Switzerland, we identified a large family in which 11 members were affected with classical autosomal dominant RP (Fig. 1A) . In this family, a genome-wide linkage analysis had resulted in a strong positive lod score of 4.08 for marker D15S205 (Fig. 1C) . Haplotype analysis restricted the shared interval to markers D15S153 and D15S127 (data not shown). As this interval contained the NR2E3 gene, the putative promoter, exons and introns of NR2E3 were directly sequenced and the causal mutation for adRP37 (MIM] 611131), c.166G4A (p.G56R), was identified in all affected individuals. None of the nonaffected family members possessed this variant nor was it found in more than 200 ethnically-matched control individuals. The patients of the Swiss family did not possess any other NR2E3 variants.
We have followed an American family since 1980, with evidence of retinal degeneration in two generations (Fig. 1B) [Gouras, 1981] . Two affected grandchildren in the third generation were included over time. The proband, Patient II-1, had a most unusual ERG that showed supernormal responses to short wavelength stimuli [Gouras et al., 1985] , which subsequently became known as the enhanced S-cone syndrome (ESCS) Marmor et al., 1990] (Fig. 2G; Supplementary Fig. S1 ). The proband had had night blindness since childhood but, remarkably, had no evidence of RP at 65 years of age with full visual fields ( Fig.  2A and B ; Table 1 ). Indeed, a dominant form of RP characterized by retinal pigmentary changes, visual field defects, night blindness, and a profound reduction in the ERG, was present in her son (Patient III-2) and her two grandchildren (Patients IV-1 and IV-2) ( Fig. 2E-G ; Table 1 ). The parents, Patients I.1 and I.2, were long deceased, but there was anecdotal evidence that the mother (Patient I.2) and her sister had vision problems, the latter being blind at an elderly age. The proband's sister (Patient II-3) had attenuated retinal vessels and massive clumped intraretinal pigmentation in her midperipheral retina ( Fig. 2C and D) . However, an electrophysiological finding suggested a more ESCSlike than adRP-like phenotype. Her response to blue light had greater amplitude than that of her nephew's (Patient III-2), whereas the converse was the case for red light (Fig. 2G) . Her dark-adapted threshold to peripheral testing was lower than that of her younger nephew's (Table 1) (Table 1) , which has declined very slowly since 1980. The other affected members of the pedigree have retained normal visual acuity.
Importantly, the proband, Patient II-1, and her sister, Patient II-3, were determined to be compound heterozygotes for two NR2E3 mutations: the most common causal mutation for ESCS p.R311Q [Haider et al., 2000] ; and the causal mutation for adRP p.G56R (Fig. 1B) . Her son (Patient III-2) and both grandchildren (Patients IV-1 and IV-2), who were all affected by adRP, had solely inherited the p.G56R mutation from their mother/grandmother and did not possess any other NR2E3 variants.
On the basis of these different clinical and genetic data, we therefore aimed at elucidating: 1) the molecular mechanisms leading to p.G56R-linked adRP; and 2) the molecular mechanisms underlying the ESCS-like phenotype in the two p.G56R/p.R311Q compound heterozygous patients.
The NR2E3-G56R Mutant Acts as a Dominant Negative Protein
Glycine 56 is located in the highly-conserved DBD of NR2E3 at the base of the a-helical DNA-binding motif of the first so-called ''zinc-finger''-like structure (Fig. 3) . To test whether the p.G56R mutation abolished DNA binding by disrupting the a-helical DNA-binding motif, we performed EMSAs with in vitro translated NR2E3 wild-type and mutant proteins on a synthetic NR2E3 response element that consisted of a direct repeat of two NR2E3 consensus binding sites spaced by one nucleotide (Fig. 4) . We observed, in the presence of the NR2E3 wild-type protein, a specific complex that had been suggested to be a NR2E3 homodimer (Fig. 4A, lane 2) [Kobayashi et al., 1999] . The specificity of binding was demonstrated by specific competition with increasing amounts of unlabeled oligonucleotides (Fig. 4A , lanes 4-7) and by nonspecific competition with an unrelated response element for Ets transcription factors (Fig. 4A, lane 3) . Further evidence of specificity was provided by the binding of anti-NR2E3 antisera to the NR2E3 complex, resulting in a slower migrating complex, appearing as a smear in the uppermost part of the lane (Fig. 4A, lane 8) . In contrast to the NR2E3 wild-type protein, no complex was observed in presence of an equivalent amount of the p.G56R protein, indicating that the mutant protein was unable to bind DNA (Fig. 4A, lanes 9-13) . Similar to NR2E3 wild-type protein, the p.R311Q protein bound the NR2E3 response element as a specific complex (Fig. 4A, lanes 14-18) . We observed a strong signal corresponding to the NR2E3 dimer in presence of both NR2E3 wild-type and p.R311Q proteins (Fig. 4A,  lane 19) , suggesting that the p.R311Q mutation located in the LBD did not impair dimerization with wild-type NR2E3.
Increasing amounts of the p.G56R protein abolished binding of both NR2E3 wild-type and p.R311Q proteins (Fig. 4B, lanes 1-6) . By decreasing the amount of p.R311Q proteins and increasing those of p.G56R, dimer binding to the radiolabeled probe became gradually weaker. Notably, in the presence of equivalent amounts of the two NR2E3 mutant proteins, which is potentially mimicking the situation in the heterozygous patients, binding of dimers to DNA was barely detected (Fig. 4B, lanes 7-11) . Taken together, this suggested that the p.G56R mutant protein was competent in dimerization, but had a dominant negative effect toward both NR2E3 wild-type and p.R311Q proteins through its inability to bind DNA. We further tested the p.G56R mutant protein in 293T cells, using luciferase reporter constructs for opsin promoter fragments (Fig. 5) . NR2E3 enhanced CRX/NRL-mediated transactivation of the rhodopsin promoter in these heterologous transactivation assays . The p.G56R mutant protein did show dominant negative activity, by abolishing NR2E3-driven potentiation of rhodopsin promoter transactivation, in the presence of either NR2E3 wild-type or p.R311Q proteins. In contrast to the transactivation of the rhodopsin promoter, NR2E3 repressed Sand M-opsin promoter activity in HEK293 cell-based assays . Surprisingly, the p.G56R mutant further enhanced the transrepression of S-and M-opsin promoters, in the presence of either wild-type or p.R311Q proteins. Importantly, there was no difference in transactivation levels of all tested opsin promoters, whether the p.G56R protein was expressed at amounts equal to the wild-type or to the p.R311Q protein, i.e., potentially mimicking NR2E3 expression of patients with genotype p.G56R/ wild-type or p.G56R/p.R311Q. Taken together, these experiments showed that dominant negative activity, i.e., competition for dimerization by a DNA binding-defective mutant, was a molecular mechanism intrinsic to the adRP-linked p.G56R mutant protein, but that this mechanism could not account for the clinical differences observed in patients with genotype p.G56R/p.R311Q affected by ESCS-like degeneration vs. patients with genotype p.G56R/wild-type affected by adRP.
Atrophins Are Corepressors of NR2E3
With the aim of elucidating the effect of the p.R311Q mutation in the proband, Patient II-1, of the American family and her sister, Patient II-3 (Fig. 1B) , we analyzed the effect of this second mutation in more detail. Arginine 311 is located in helix 7 of the NR2E3 LBD (Fig. 3B) . This region participates in the binding of specific ligands to nuclear receptors [Li et al., 2005] . Ligand binding, in turn, regulates cofactor recruitment on nuclear receptors [Nettles and Greene, 2005] . As NR2E3 represses conespecific genes in rod photoreceptors Cheng et al., 2006; , we hypothesized that the p.R311Q mutation might alter the binding to corepressors. The recent description of atrophins as corepressors of NR2E1 [Wang et al., 2006; Zhang et al., 2006] , and the high amino acid sequence homology between NR2E1 and NR2E3 (Fig. 3C) , prompted us to test atrophins in 293T cell-based transactivation assays for repressor activity on NR2E3 (Fig. 6A) . Atrophins enhanced the NR2E3-mediated repression on the M-opsin promoter by over 30% when expressed in two-fold excess and by over 50% when Figure 3 . NR2E3 protein structure. A: The NR2E3 DNA-binding domain (DBD) folds into two ''zinc finger''-like structures. In the zinc fingers, the a-helical DNA binding motifs lie perpendicular to each other; one a-helix in each zinc finger, labeled HZnf1 and HZnf2. The p.G56R mutation is located at the basis of the a-helix of the first zinc finger. B: The NR2E3 ligand-binding domain (LBD) presents a canonical a-helical structure forming a hydrophobic ligand-binding pocket. R311 is located at the end of helix 7 (H7). Modeling of the mutant protein suggests a slight destabilization of the a-helical turn immediately C-terminal of R311 (orange dots). Ligand-binding involves residues of H7, but is mainly mediated by H3, H6, and HAF (AF-2: Activator Function-2). The dimerization interface is mainly located in H9 and H10. Modeling was performed with SWISSMODEL [Schwede et al., 2003] . C: Human (hs) NR2E1 and NR2E3 amino acid sequences were aligned with the ClustalW 1.83 algorithm [Chenna et al., 2003] . A/B: N-terminal A/B domain; C: DBD; D: hinge region; E/F: LBD. Identical amino acids are denoted by arrows, conserved amino acids by dots. In the DBD, the two zinc fingers are indicated by dotted lines. In the LBD, a-helices (H) and b-sheets (s) are indicated by black boxes. A bold line underlines the C-terminal part of the NR2E1 LBD sufficient for NR2E1/atrophin-1 interaction [Wang et al., 2006; Zhang et al., 2006] . The sites of p.G56R and p.R311Q mutations are indicated by red letters in the NR2E3 sequence. present in three-fold excess. In contrast, NCoR, a reported corepressor for class I nuclear hormone receptors [Hörlein et al., 1995] , did not enhance M-opsin repression. By in situ hybridization experiments, atrophin-1 was detected throughout the retina, with the highest levels in ganglion cells, at the inner limit of the inner nuclear layer where the amacrine cells are preferentially located, and in the inner segments of the photoreceptors (Fig. 6B) . In contrast, atrophin-2 mRNA was not detected in photoreceptors (data not shown). Consistent with a role in the repression of conespecific genes, atrophin-1 was associated with the proximal Mopsin promoter, as tested by chromatin-immunoprecipitations in adult mouse retinas (Fig. 6C) . Expression of atrophin-1 in photoreceptors where NR2E3 is expressed, and association of atrophin-1 to a NR2E3-regulated promoter in vivo, suggested that atrophin-1 was a physiologically relevant corepressor of NR2E3.
The NR2E3-R311Q Mutant Is Defective in AtrophinDependent M-Opsin Repression
To test our hypothesis that NR2E3 wild-type and p.R311Q proteins differentially interacted with corepressors, we performed transactivation assays in 293T cells (Fig. 6A) . When present in a three-fold excess, atrophin-1 repressed the M-opsin promoter by over 50% in the presence of wild-type NR2E3 protein, but failed to repress the M-opsin promoter in the presence of the NR2E3-R311Q protein (P 5 0.009). The same was observed to a lesser extent with atrophin-2 (P 5 0.047). Consistent with a specific binding of atrophins to NR2E3, no difference in M-opsin repression between NR2E3 wild-type and p.R311Q proteins was observed in the presence of NCoR. These results suggested that impaired corepressor binding is the molecular basis of ESCS.
Discussion
The aims of the present work were as follows: 1) to characterize the p.G56R mutation causing adRP; and 2) to elucidate why the presence of two mutations in the compound heterozygotes (p.G56R/p.R311Q) resulted in an ESCS-like phenotype and in 1 of the 2 cases a much milder phenotype, whereas the presence of the p.G56R mutation alone resulted in rapidly progressing adRP. , along with increasing amounts of atrophin-1, atrophin-2, and NCoR (33 ng, 66 ng, or 100 ng). At least three independent experiments were performed in duplicate in 12-well plates using the luciferase assay system (Promega). Luciferase activity was normalized to b-galactosidase activity. Normalized luciferase activities of cells transfected without corepressors were set to 1. Error bars represent standard error of the mean (SEM); Ã Po0.05; ÃÃ Po0.01. B: In situ hybridization for atrophin-1 mRNAs on retinal sections of 2-month-old Bl6/C57. RPE, retinal pigment epithelium; POS, photoreceptor outer segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Note the absence of signal in presence of the control sense probe. Scale bar: 50 mm. C: Atrophin-1 associates with the M-opsin promoter in vivo. Chromatinimmunoprecipitation for the M-opsin promoter was performed with anti-atrophin-1 antisera (a-atn-1) on retinas of 2-month-old C57/BL6 mice. As controls, immunoprecipitation without antisera (no antibody [no Ab]) or with the buffer alone (mock) were used. PCR amplifications on total input chromatin (Total input) are shown in the lower panel.
Dominant Negative Activity of the adRP-Causing NR2E3-p.G56R Mutant Protein
We have reported two new families affected by adRP caused by the p.G56R mutation in the NR2E3 gene. This mutation is unique among the reported causal NR2E3 mutations, because it acts in a dominant manner and is located in the first Zn-finger of the DBD. Indeed, the majority of ESCS patients carry mutations in the LBD. The few ESCS patients with mutations in the DBD are either homozygous (G88V, R97H) or compound heterozygous for the common intron 1 splice-acceptor mutation (IVS1-2A4C) and R76Q, R76W, R104W or deletion p.65-67 [Haider et al., 2000; Wright et al., 2004] . This latter mutation deletes the P-box located at the C-terminus of the first zinc finger, whereas the other mutations are located in the second zinc finger or in the Cterminal extension of the DBD. Whether these ESCS-linked mutations affect DNA-binding and/or dimerization needs to be determined.
Our functional data showed that the absence of DNA-binding, but competition for dimer formation, explained the dominant negative activity exhibited by the p.G56R mutant protein. This provided a molecular basis for the adRP observed in the patients. Indeed, if the mutant protein had failed to dimerize, the NR2E3 wild-type protein transcribed from the healthy allele in heterozygous individuals might have been sufficient to maintain normal NR2E3 activity.
The cell-based transactivation studies were useful to functionally characterize the dominant negative activity of the p.G56R mutant protein, but physiological interpretation of these data should be done with caution. On the one hand, the modest decrease by less than 50% in rhodopsin promoter transactivation by transfecting equivalent amounts of NR2E3 wild-type and p.G56R proteins, i.e., the ratio one might expect to occur in heterozygous adRP patients, could be significant in vivo. Indeed, mice expressing about 50% of the rhodopsin levels observed in wild-type mice, showed a clear reduction in rod function, decreased length of photoreceptor outer segments at P15, and thinning of the outer nuclear layer by one to two rows at P90 [Lem et al., 1999] . On the other hand, the surprising observation that the p.G56R mutant protein increased the repression of both Sand M-opsin genes in the heterologous transactivation assays, was different from in vivo data, where S-opsin mRNA expression was derepressed in rd7/rd7 mice, but not that of M-opsin mRNA expression Corbo and Cepko, 2005] . Alternatively, the increase of S-and M-opsin repression by the p.G56R mutant protein could be attributed to inhibition of an activator protein. The competition between DNA-binding and activator-binding existing for the NR2E3 wild-type protein would then be shifted solely toward activator-binding for the p.G56R mutant protein, resulting in a drop of promoter activity. With respect to this latter potential mechanism, it will be interesting to determine if the p.G56R mutation alters physical interactions with the transcriptional activator CRX . Impaired Corepressor-Binding by the ESCS-Linked NR2E3-p.R311Q Mutant Protein Individuals carrying the ESCS-causing p.R311Q mutation at a heterozygous state did not show any clinical phenotype [Haider et al., 2000] . But a beneficial effect of this mutation was uncovered in the compound heterozygous patients of the American family, in whom it cosegregated with the adRP-causing p.G56R mutation. Strikingly, the ERG of the proband, Patient II-1, remained stationary for 25 years with a classical ESCS phenotype. This also indicated that the p.R311Q mutation was functionally dominant to the p.G56R mutation.
The heterologous transactivation assays clearly showed that the p.R311Q mutant protein failed to repress the M-opsin promoter in presence of atrophin corepressors, suggesting that impaired corepressor-binding was the molecular basis of ESCS. A beneficial effect of the recessive p.R311Q mutation in presence of the dominant p.G56R mutation, might therefore be due to increased photoreceptor-specific gene expression caused by impaired repression. As ligands for NR2E3 are not yet available [Wolkenberg et al., 2006] , we could not test: 1) if the p.R311Q mutation altered the specificity and the affinity toward endogenous ligands and the altered ligand binding caused corepressor release; 2) if the p.R311Q mutation induced a subtle conformational change in the LBD, permitting a corepressor/coactivator exchange; and, 3) if corepressors were bound to unliganded and/or ligand-bound NR2E3. It has to be mentioned that the p.R311Q mutation is located outside the atrophin-binding region identified for NR2E1 [Wang et al., 2006; Zhang et al., 2006] . Consistently, in transactivation assays in Y79 human retinoblastoma cells, the corepressor Ret-CoR, structurally unrelated to atrophins, also failed to repress the cyclin D1 promoter in the presence of the p.R311Q mutant protein [Takezawa et al., 2007] . These results also showed that NR2E3 repressive activity might be mediated by distinct corepressor complexes, namely during development and in the adult retina.
Whatever the exact molecular mechanisms mediated by the p.R311Q mutation are, they cannot alone explain the clinical differences observed in the proband, Patient II-1, and her sister, Patient II-3. Modifier effects of unknown (or not tested) genes and/or environmental influences are likely to be involved. Interestingly, an extensive variability in ESCS disease expression has been described in patients with homozygous p.R311Q mutations; e.g., abundance of clumped retinal pigments and rates of retinal degeneration [Audo et al., 2008; Chavala et al., 2005; Gerber et al., 2000; Haider et al., 2000; Hayashi et al., 2005; Milam et al., 2002; Sharon et al., 2003; Wright et al., 2004] . Our observation that atrophins had to be overexpressed in cell-based transactivation assays to see an effect of the p.R311Q mutation on transactivation of target genes suggests that corepressor levels could contribute to these clinical differences in p.R311Q/p.G56R compound heterozygotes and in p.R311Q/p.R311Q homozygotes.
In conclusion, and based on our experimental data, loss of interaction with a corepressor is a plausible model for how the p.R311Q mutant protein causes ESCS. Understanding the exact mode of action of the p.R311Q mutant protein may open the provocative perspective of introducing by gene therapy the mutant p.R311Q protein in adRP patients carrying the p.G56R mutation, to slow down the progression of adRP.
